We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Preliminary study data on Merck’s experimental painkiller Arcoxia show it presents thrombotic cardiovascular risks similar to a commonly used anti-inflammatory drug, but other findings suggest that more work needs to be done before Arcoxia is finally approved for the U.S. market.
Roche’s acne drug Accutane, already known to cause birth defects, may raise the risk for patients to develop other health problems, according to a study published in the August issue of Archives of Dermatology.
By 2010, generics will dominate the schizophrenia drug market, and Pfizer will be the only major drug firm to maintain a strong position after its current leading antipsychotic goes generic, according to a report by research firm Datamonitor.
The SEC has agreed Aug. 9 to give smaller public companies additional time to comply with the internal control requirements under the Sarbanes-Oxley Act (SOX), prompting the Biotechnology Industry Organization’s (BIO) praise.
Global pharmaceutical drug sales have remained steady over the past several months, averaging 5 percent growth, healthcare consultant IMS Health reported.
Sanofi-aventis and Bristol-Myers Squibb (BMS) are trying to stop Apotex from selling its generic version of their blockbuster blood thinner Plavix by seeking a preliminary injunction in a U.S. federal court, but a patent agreement they signed with Apotex may prevent them from getting it, according to one legal expert.
An Aug. 15 article in the Annals of Internal Medicine proposing that the FDA and other regulatory agencies must step up to stem the tide of what it calls unscrupulous drug marketing practices is bringing to the fore the question of who is in the best position to police the drug marketing system.
VaxGen’s experimental anthrax vaccine could be a viable alternative to the presently available treatment, according to a study published in the August issue of the medical journal Vaccine.
Intranasal Therapeutics has received more than $39 million in venture capital to finish developing two nasal sprays — one to treat wounded U.S. soldiers being evacuated from combat zones in the Middle East, and one to treat victims of nerve gas attacks.